AUTHOR=Fuchs Anke , Gliwiński Mateusz , Grageda Nathali , Spiering Rachel , Abbas Abul K. , Appel Silke , Bacchetta Rosa , Battaglia Manuela , Berglund David , Blazar Bruce , Bluestone Jeffrey A. , Bornhäuser Martin , ten Brinke Anja , Brusko Todd M. , Cools Nathalie , Cuturi Maria Cristina , Geissler Edward , Giannoukakis Nick , Gołab Karolina , Hafler David A. , van Ham S. Marieke , Hester Joanna , Hippen Keli , Di Ianni Mauro , Ilic Natasa , Isaacs John , Issa Fadi , Iwaszkiewicz-Grześ Dorota , Jaeckel Elmar , Joosten Irma , Klatzmann David , Koenen Hans , van Kooten Cees , Korsgren Olle , Kretschmer Karsten , Levings Megan , Marek-Trzonkowska Natalia Maria , Martinez-Llordella Marc , Miljkovic Djordje , Mills Kingston H.G. , Miranda Joana P. , Piccirillo Ciriaco A. , Putnam Amy L. , Ritter Thomas , Roncarolo Maria Grazia , Sakaguchi Shimon , Sánchez-Ramón Silvia , Sawitzki Birgit , Sofronic-Milosavljevic Ljiljana , Sykes Megan , Tang Qizhi , Vives-Pi Marta , Waldmann Herman , Witkowski Piotr , Wood Kathryn J. , Gregori Silvia , Hilkens Catharien M. U. , Lombardi Giovanna , Lord Phillip , Martinez-Caceres Eva M. , Trzonkowski Piotr TITLE=Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization JOURNAL=Frontiers in Immunology VOLUME=8 YEAR=2018 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.01844 DOI=10.3389/fimmu.2017.01844 ISSN=1664-3224 ABSTRACT=

Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.